Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Dec 2018
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational
- Acronyms RAMSES OLE
- Sponsors Aimmune Therapeutics
- 19 Dec 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2018 Planned number of patients changed from 300 to 330.